Fig. 5
Distribution of acquired resistance mechanism of patients who progressed from A EGFR-TKI monotherapy (T) or B EGFR-TKI with bevacizumab (A+T)
Fig. 5 | BMC Medicine
Distribution of acquired resistance mechanism of patients who progressed from A EGFR-TKI monotherapy (T) or B EGFR-TKI with bevacizumab (A+T)